St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C γ and ε activity

Biochemical Pharmacology

Volumn 79, Issue 9, 2010, Pages 1327-1336

  Galeotti, Nicoletta ^a   Vivoli, Elisa ^a   Bilia, Anna Rita ^a   Vincieri, Franco Francesco ^a   Ghelardini, Carla ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hyperforin; Hypericin; Hypericum perforatum; Neuropathic pain; PKC; St. John's Wort

Indexed keywords

AMITRIPTYLINE; CHLOROFORM; FLAVONOID; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPERIN; ISOQUERCITRIN; METHANOL; NALOXONE; NAPHTHODIANTHRONE; OXALIPLATIN; PHLOROGLUCINOL; PROTEIN KINASE C EPSILON; PROTEIN KINASE C GAMMA; QUERCETIN; QUERCITRIN; RUTOSIDE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HYPERALGESIA; IMMUNOBLOTTING; LOCOMOTION; LOW DRUG DOSE; MALE; MOTOR COORDINATION; NERVE COMPRESSION; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROTAROD TEST; SCIATIC NERVE; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; HYPERICUM; MALE; PAIN; PERYLENE; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77649190706     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.016     Document Type: Article

References (42)

1. Woolf C.J., and Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353 (1999) 1959-1964
2. Cruccu G., Anand P., Attal N., Garcia-Larrea L., Haanpää M., Jørum E., et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11 (2004) 153-162
3. Hansson P.T., and Dickenson A.H. Pharmacological treatments of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 113 (2005) 251-254
4. Sindrup S.H., and Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
5. Kingery S.W. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 73 (1997) 123-129
6. Koltzenburg M. Painful neuropathies. Curr Opin Neurol 11 (1998) 515-521
7. Kalso E., Edward J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain: a systematic review of efficacy and safety. Pain 112 (2004) 372-380
8. Wallace M.S. Diagnosis and treatment of neuropathic pain. Curr Opin Anaesth 18 (2005) 548-554
9. Davis J.L., Lewis S.B., Gerich J.E., Kaplan R.A., Schultz T.A., and Wallin D.J. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. J Am Med Assoc 238 (1977) 2291-2292
10. Dworkin R.H., Backonja M., Rowbotham M.C., Allen R.R., Argoff C.R., Bennett G.J., et al. Advances in neuropathic pain: diagnosis, mechanisms and treatment recommendations. Arch Neurol 60 (2003) 1524-1534
11. Owen R.T. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 43 (2007) 857-863
12. Rowbotham M.C., Davies P.S., Verkempinck C., and Galer B.S. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 65 (1996) 39-44
13. Beniczky S., Tajti J., Tímea Varga E., and Vécsei L. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm 112 (2005) 735-749
14. Cohen H.W., Gibson G., and Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 108 (2000) 2-8
15. Linde K., Mulrow C.D., Berner M., and Egger M. St. John's Wort for depression. Cochrane Database Syst Rev 2 (2005) CD000448
16. Greeson J.M., Sanford B., and Monti D.A. St. John's Wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 153 (2001) 402-414
17. Suzuki O., Katsumata Y., Oya M., Bladt S., and Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Med 50 (1984) 272-274
18. Kubin A., Wierrani F., Burner U., Alth G., and Grünberger W. Hypericin - the facts about a controversial agent. Curr Pharmac Des 11 (2005) 233-253
19. Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., and Muller W.E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63 (1998) 499-510
20. Chatterjee S.S., Noldner M., Koch E., and Erdelmeier C. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31 Suppl. 1 (1998) 7-15
21. Muller W.E., Singer E., Wonnemann M., Hafner U., Rolli M., and Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31 Suppl. 1 (1998) 16-21
22. Gobbi M., Dalla Valle F., Ciapparelli C., Diomede L., Morazzoni P., Verotta L., et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in the rat brain. N-S Arch Pharmacol 360 (1999) 262-269
23. Nathan P. The experimental and clinical pharmacology of St. John's Wort (Hypericum perforatum L.). Mol Psychiatry 4 (1999) 333-338
24. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
25. Cavaletti G., Tredici G., Petruccioli M.G., Dondè E., Tredici P., Marmiroli P., et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37 (2001) 2457-2463
26. 3 pathway is involved in muscarinic antinociception. Neuropsychopharmacology 28 (2003) 888-897
27. Brolis M., Gabetta B., Fuzzati N., Pace R., Panzeri F., and Peterlongo F. Identification by high-performance liquid chromatography-diode array detection-mass spectrometry and quantification by high performance liquid chromatography-UV absorbance detection of active constituents of Hypericum perforatum. J Chromatogr A 825 (1998) 9-16
28. Sindrup S.H., Madsen C., Bach F.W., Gram L.F., and Jensen T.S. St. John's Wort has no effect on pain polyneuropathy. Pain 91 (2000) 361-365
29. Uchida S., Hirai K., Hatanaka J., Hanato J., Umegaki K., and Yamada S. Antinociceptive effects of St. John's Wort, Harpagophytum procumbens extract and grape seed proantocyanidins extract in mice. Biol Pharm Bull 31 (2008) 240-245
30. Simmen U., Schweitzer C., Burkard W., Schaffner W., and Lundstrom K. Hypericum perforatum inhibits the binding of mu- and kappa-opioid receptor expressed with the Semliki Forest virus system. Pharm Acta Helv 73 (1998) 53-56
31. Simmen U., Higelin J., Berger-Büter K., Schaffner W., and Lundstrom K. Neurochemical studies with St. John's Wort in vitro. Pharmacopsychiatry 34 Suppl. 1 (2001) S137-S142
32. Tedeschi E., Menegazi M., Margotto D., Suzuki H., Forstermann U., and Kleinert H. Anti-inflammatory actions of St. John's Wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1 alpha (STAT-1 alpha) activation. J Pharmacol Exp Ther 307 (2003) 254-261
33. Meotti F.C., Luiz A.P., Pizzolatti M.G., Kassuya C.A.L., Calixto J.B., and Santos A.R. Analysis of the antinociceptive effect of the flavonoid myricitrin: evidence for a role of the l-arginine nitric-oxide and protein kinase C pathways. J Pharmacol Exp Ther 316 (2006) 789-796
34. Takahashi I., Nakanishi S., Kobayashi E., Nakano H., Suzuki K., and Tamaoki T. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophys Res Commun 165 (1989) 1207-1212
35. Ferriola P.C., Cody V., and Middleton Jr. E. Protein kinase C inhibition by plant flavonoids. Biochem Pharmacol 38 (1989) 1617-1624
36. Velàzquez K.T., Mohammad H., and Sweitzer S.M. Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res 55 (2007) 578-589
37. Way K.J., Chou E., and King G.L. Identification of PKC-isoforms-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 21 (2000) 181-187
38. Malmberg A.B., Chen C., Tonegawa S., and Basbaum A.I. Preserved acute pain and reduced neuropathic pain in mice lacking PKCγ. Science 278 (1997) 279-283
39. Dina O.A., Chen X., Reichling D., and Levine J.D. Role of protein kinase Cε and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 108 (2000) 507-515
40. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 258 (1992) 607-615
41. Kim H.P., Park H., Son K.H., Chang H.W., and Kang S.S. Biochemical pharmacology of biflavonoids: implications for anti-inflammatory action. Arch Pharm Res 31 (2008) 265-273
42. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., et al. Pharmacological management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251